AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 160
- Registration Number
- NCT00239343
- Locations
- 🇸🇪
Research Site, Lund, Sweden
🇩🇰Research Stie, Herlev, Denmark
Budesonide / Formoterol in Treatment of Exacerbations of COPD
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00239278
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 824
- Registration Number
- NCT00239330
- Locations
- 🇧🇪
Research Site, Sint-Agatha-Berchem, Belgium
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17802
- Registration Number
- NCT00239681
- Locations
- 🇻🇪
Research Site, Punto Fijo, Estado Falcon, Venezuela
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00239304
- Locations
- 🇫🇮
Research Centre, Helsinki, Finland
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00238797
- Locations
- 🇸🇪
Research Site, Umeå, Sweden
SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2008-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1300
- Registration Number
- NCT00238784
- Locations
- 🇨🇦
Research Site, Brampton, Ontario, Canada
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT00237900
- Locations
- 🇫🇮
Reseach Site, Helsinki, Finland
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00235911
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00235937
© Copyright 2024. All Rights Reserved by MedPath